Synmosa Biopharma Stock Current Valuation
| 4114 Stock | TWD 34.40 0.40 1.15% |
Valuation analysis of Synmosa Biopharma helps investors to measure Synmosa Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Synmosa Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Synmosa Biopharma is based on 3 months time horizon. Increasing Synmosa Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Synmosa stock is determined by what a typical buyer is willing to pay for full or partial control of Synmosa Biopharma. Since Synmosa Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Synmosa Stock. However, Synmosa Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 34.4 | Real 35.31 | Hype 34.4 | Naive 34.05 |
The intrinsic value of Synmosa Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Synmosa Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Synmosa Biopharma helps investors to forecast how Synmosa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Synmosa Biopharma more accurately as focusing exclusively on Synmosa Biopharma's fundamentals will not take into account other important factors: Synmosa Biopharma Company Current Valuation Analysis
Synmosa Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Synmosa Biopharma Current Valuation | 17.93 B |
Most of Synmosa Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Synmosa Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Synmosa Biopharma has a Current Valuation of 17.93 B. This is 24.86% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all Taiwan stocks is 7.88% lower than that of the firm.
Synmosa Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Synmosa Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Synmosa Biopharma could also be used in its relative valuation, which is a method of valuing Synmosa Biopharma by comparing valuation metrics of similar companies.Synmosa Biopharma is currently under evaluation in current valuation category among its peers.
Synmosa Fundamentals
| Return On Equity | 0.0894 | |||
| Return On Asset | 0.0223 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 17.93 B | |||
| Shares Outstanding | 327.14 M | |||
| Shares Owned By Insiders | 25.42 % | |||
| Shares Owned By Institutions | 0.90 % | |||
| Price To Earning | 14.65 X | |||
| Price To Book | 3.09 X | |||
| Price To Sales | 4.06 X | |||
| Revenue | 3.23 B | |||
| Gross Profit | 1.29 B | |||
| EBITDA | 507.92 M | |||
| Net Income | 303.86 M | |||
| Cash And Equivalents | 1.28 B | |||
| Cash Per Share | 3.96 X | |||
| Total Debt | 2.27 B | |||
| Debt To Equity | 0.50 % | |||
| Current Ratio | 1.86 X | |||
| Book Value Per Share | 15.83 X | |||
| Cash Flow From Operations | 444.29 M | |||
| Earnings Per Share | 2.34 X | |||
| Target Price | 50.0 | |||
| Number Of Employees | 16 | |||
| Beta | 0.34 | |||
| Market Capitalization | 15.75 B | |||
| Total Asset | 10.32 B | |||
| Z Score | 3.6 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 0.58 % | |||
| Net Asset | 10.32 B | |||
| Last Dividend Paid | 0.46 |
About Synmosa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Synmosa Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Synmosa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Synmosa Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Synmosa Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Synmosa Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synmosa Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Synmosa Stock
Moving against Synmosa Stock
| 0.92 | 9904 | Pou Chen Corp | PairCorr |
| 0.85 | 2881A | Fubon Financial Holding | PairCorr |
| 0.77 | 2882B | Cathay Financial Holding | PairCorr |
| 0.69 | 4123 | Center Laboratories | PairCorr |
| 0.63 | 2881B | Fubon Financial Holding | PairCorr |
The ability to find closely correlated positions to Synmosa Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Synmosa Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Synmosa Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Synmosa Biopharma to buy it.
The correlation of Synmosa Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Synmosa Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Synmosa Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Synmosa Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.